Release date: 2015-10-14
Olathetan monopoly
Olalistam was developed by the Italian company Skhibim, and was launched in 1987. At present, there are 4 injections, 2 capsules and 1 powder needle in China.
According to data from 22 domestic sample hospitals, Olaracetam has been in a high-speed growth trend from 2005 to 2014, with a compound annual growth rate of 60.2%. In 2005, the amount of oxiracetam in the sample hospital was 17.76 million yuan; in 2014, the amount of medicine used was 1.24 billion yuan. Since the listing of Oxiacetam, the market has expanded rapidly. Among the affiliated puzzle drugs, Oxacetam has topped the list and is in a stable position.
At present, there are only four companies that have obtained approval for the production of oxiracetam preparations in China: Guangdong Shixin Pharmaceutical, Shijiazhuang Pharmaceutical Group, Ouyi Pharmaceutical, Sanlian Pharmaceutical and Hunan Jianlang Pharmaceutical. The market for this variety is monopolized by domestically produced drugs. In 2014, Guangdong Shixin Pharmaceutical's “Bai Qingxing†sales amounted to 420 million yuan, accounting for 34.2% of the share; Shijiazhuang Pharmaceutical Group's “Ou Lai Ning†sales of “Ou Lai Ning†was 380 million yuan, accounting for 31.3% of the shares. Heilongjiang Harbin Sanlian Pharmaceutical's "Oulan Tong" sales of 330 million yuan, accounting for 26.4% share; Hunan Jianlang Pharmaceutical's "Jianlangxing" sales of 100 million yuan, accounting for 8.3%.
Shijiazhuang Pharmaceutical Group's powder injection from Ouyi Pharmaceutical has quickly occupied the market since its listing in 2010. In 2014, sales reached 250 million yuan, accounting for 19.9% ​​of the entire market. In the next few years, with the emergence of more new dosage forms, the increase in competitive companies will diversify the market.
Donepezil tablets
Donepezil was developed by Japan Eisai Pharmaceutical Co., Ltd. In 1999, it was listed in China under the trade name “Anli Shenâ€. At present, 14 companies have approved the production of donepezil preparations in China. The main dosage forms include tablets, dispersible tablets, orally disintegrating tablets and capsules.
According to data from 22 domestic sample hospitals, donepezil has been in a continuous growth trend from 2005 to 2014, with a compound annual growth rate of 23.3%. From 2005 to 2014, the amount of medication increased by 6.6 times. The domestic market is mainly based on tablets, with sales of 130 million yuan, accounting for 99.3%; capsule sales of 920,000 yuan, accounting for only 0.7%, the domestic tablet market dominates.
In 2014, the number of donepezil production enterprises involved in the sample hospital reached 12, among which the top three companies were: Eric (Suzhou) Pharmaceutical's “Anli Shen†sales of 120 million yuan, accounting for 89.5%; Jiangsu Haosen The sales of the “Shi Le Pu Pu†of the pharmaceutical industry was 6.21 million yuan, accounting for 4.6%; the sales of “Aris†of Shaanxi Western Zhou Pharmaceuticals was 3.02 million yuan, accounting for 2.3%; other enterprises accounted for 3.7%. The domestic market is dominated by the imported product “Anli Shenâ€. The domestically-developed enterprises are Jiangsu Haosen Pharmaceutical and Shaanxi Western Zhou Pharmaceutical, which are both above 20.0%. In 2009, donepezil entered the national medical insurance catalogue and played a favorable role in promoting the market.
US King Kong Import Monopoly
The US King Kong was developed by the Danish Lingbei Company and entered the Chinese market in 2006. The trade name is “Yi Bei Shenâ€. In July 2013, Zhuhai Federal Pharmaceutical's Memantine tablets and oral solutions were approved for marketing, and the trade name was “Yi Bingqingâ€. At present, there are more than 50 enterprises that are applying for this product in China. In addition to tablets and oral solutions, the reported dosage forms mainly include capsules, sustained-release capsules, dispersible tablets, orally disintegrating tablets and injections.
According to the data of 22 domestic sample hospitals, from 2007 to 2014, the compound growth rate of memantine drugs was as high as 59.9%, and the overall market growth in 2 years was 26.7 times. In 2014, the amount of medication used by Yishen Shen was 79.16 million yuan, accounting for 99.7% of the total, up 19.4% over the same period. The growth rate was full and the absolute dominant position in the domestic market. Zhuhai Federal Pharmaceutical's “Yi Bing Qing†has been sold in the market in 2014, but the sales are not large.
Source: Pharmaceutical Economics
Dental Cleaner,Dental Cleaning Machine,Ultrasonic Dental Cleaner,Best Dental Ultrasonic Cleaner
ZHEJIANG FOMOS MEDICAL TECHNOLOGY CO.,LTD. , https://www.ifomos.com